Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

13.08
-0.9000-6.44%
Post-market: 13.610.5300+4.05%19:50 EDT
Volume:2.24M
Turnover:29.64M
Market Cap:1.80B
PE:-2.54
High:13.90
Open:13.75
Low:12.83
Close:13.98
Loading ...

Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

Insider Monkey
·
22 Nov 2024

Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Nov 2024

Arrowhead Pharmaceuticals’ Potential Approval of Clozasiran Drives Buy Rating and $60 Price Target

TIPRANKS
·
21 Nov 2024

Piper Sandler Sticks to Its Buy Rating for Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
19 Nov 2024

Arrowhead Files Plozasiran New Drug Application in Familial Chylomicronemia Syndrome

MT Newswires Live
·
18 Nov 2024

BRIEF-Arrowhead Pharmaceuticals submits New Drug Application To U.S. FDA

Reuters
·
18 Nov 2024

BRIEF-Arrowhead Pharmaceuticals Presents New Data At Aha24

Reuters
·
18 Nov 2024

Arrowhead announces new PALISADE study results

TIPRANKS
·
18 Nov 2024

Arrowhead Pharmaceuticals Inc - Palisade Study Met Primary and Secondary Endpoints

THOMSON REUTERS
·
18 Nov 2024

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

THOMSON REUTERS
·
18 Nov 2024

Arrowhead Pharmaceuticals Inc - to Submit Plozasiran Applications to Other Regulators in 2025

THOMSON REUTERS
·
18 Nov 2024

Arrowhead Pharmaceuticals: Mean Reductions in Triglycerides of up to -73% in Patients From Muir and -86% in Patients From Shasta-2 in Study

THOMSON REUTERS
·
18 Nov 2024

Arrowhead Pharmaceuticals Presents New Data at Aha24 From Palisade Phase 3 Study and Open-Label Extension From Muir and Shasta-2 Studies of Plozasiran

THOMSON REUTERS
·
18 Nov 2024

Arrowhead Pharmaceuticals: Plozasiran Induced Deep and Sustained Reductions in Triglycerides

THOMSON REUTERS
·
18 Nov 2024